A Relative Bioavailability Study of Quinine Sulfate Capsules Under Fasting and Fed Conditions

Phase 1 Completed 27 enrolled Mutual Pharmaceutical Company, Inc.

RandomizedCrossoverDouble-blindBasic science

Summary

The purpose of this study is to evaluate and compare the relative bioavailability of Quinine Sulfate 324 mg capsules, manufactured by the Mutual Pharmaceutical Company, to Quinine Sulphate 300 mg tablets, manufactured by the Government Pharmaceutical Organization, Bangkok Metropolis, Thailand, after single oral dose administration under fasting conditions. An additional purpose of this study is to evaluate the effect of food on the Mutual Pharmaceutical Company product.

Timeline

Start: 2004-02
Primary completion: 2004-03
Completion: 2004-03

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Quinine	Small molecule	300 mg	Oral
Subject	Quinine	Small molecule	324 mg	Oral

Indications

No indication recorded.